Literature DB >> 11642718

Time-dependent oxidative stress caused by benznidazole.

R C Pedrosa1, A F De Bem, C Locatelli, R C Pedrosa1, R Geremias, D Wilhelm Filho.   

Abstract

Benznidazole (BZN) is a nitroimidazole derivative which has a notable trypanocide activity, and it is the only drug used in Brazil and Argentina for the treatment of Chagas' disease. The drug in current use is thought to act, at least in part, by inducing oxidative stress within the parasite. Imidazolic compounds are involved in the production of reactive oxygen species (ROS). In order to evaluate the effect of BZN on ROS production and on the antioxidant status of the host, male rats were treated for different periods of time (2, 4, 6, 10 and 30 days) with 40 mg BZN/kg body weight. After treatment, biomarkers of oxidative stress such as the activities of catalase (CAT), superoxide dismutase (SOD), glutathione-S-transferase (GST) and glutathione reductase (GR), and also thiobarbituric acid reactive species (TBARS), reduced glutathione (GSH), total glutathione (TG) and oxidized glutathione (GSSG) concentrations, were measured in crude hepatic homogenates. Our results revealed that BZN is able to cause tissue damage as shown by increased TBARS content, inhibition of some antioxidants and induction of other antioxidants in a concentration- and time-dependent manner. The tissue damage measured as TBARS increased up to the 10th day of treatment. GST activity was inhibited during the BZN treatment. On the other hand, CAT and GR showed similar increased activities at the beginning, followed by decreased activities at the end of the treatment. After 30 days of treatment, GR activity remained low while CAT activity was high, compared to controls. The SOD activities remained unchanged throughout the experimental period. GSH showed lower values at the beginning of BZN treatment but the hepatic concentrations were enhanced at the end of the experimental period. Total glutathione showed a similar profile, and oxidized glutathione showed higher values in rats treated with BZN. In conclusion, these results indicate that, at therapeutic doses, BZN treatment elicits an oxidative stress in rat hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11642718     DOI: 10.1179/135100001101536328

Source DB:  PubMed          Journal:  Redox Rep        ISSN: 1351-0002            Impact factor:   4.412


  18 in total

1.  In vitro and in vivo trypanocidal effects of the cyclopalladated compound 7a, a drug candidate for treatment of Chagas' disease.

Authors:  Alisson L Matsuo; Luis S Silva; Ana C Torrecilhas; Bruno S Pascoalino; Thiago C Ramos; Elaine G Rodrigues; Sergio Schenkman; Antonio C F Caires; Luiz R Travassos
Journal:  Antimicrob Agents Chemother       Date:  2010-05-17       Impact factor: 5.191

2.  Benefits of Ascorbic Acid in Association with Low-Dose Benznidazole in Treatment of Chagas Disease.

Authors:  Maiara Voltarelli Providello; Zumira Aparecida Carneiro; Gisele Bulhões Portapilla; Gabriel Tavares do Vale; Ricardo Souza Camargo; Carlos Renato Tirapelli; Sérgio de Albuquerque
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

3.  Mechanism of Trypanosoma cruzi death induced by Cratylia mollis seed lectin.

Authors:  M P Fernandes; N M Inada; M R Chiaratti; F F B Araújo; F V Meirelles; M T S Correia; L C B B Coelho; M J M Alves; F R Gadelha; A E Vercesi
Journal:  J Bioenerg Biomembr       Date:  2010-02-13       Impact factor: 2.945

4.  Trypanosoma cruzi infection and benznidazole therapy independently stimulate oxidative status and structural pathological remodeling of the liver tissue in mice.

Authors:  Rômulo Dias Novaes; Eliziária C Santos; Marli C Cupertino; Daniel S S Bastos; Jerusa M Oliveira; Thaís V Carvalho; Mariana M Neves; Leandro L Oliveira; André Talvani
Journal:  Parasitol Res       Date:  2015-04-28       Impact factor: 2.289

5.  The trypanocidal benznidazole promotes adaptive response to oxidative injury: Involvement of the nuclear factor-erythroid 2-related factor-2 (Nrf2) and multidrug resistance associated protein 2 (MRP2).

Authors:  Juan Pablo Rigalli; Virginia Gabriela Perdomo; Nadia Ciriaci; Daniel Eleazar Antonio Francés; María Teresa Ronco; Amy Michele Bataille; Carolina Inés Ghanem; María Laura Ruiz; José Enrique Manautou; Viviana Alicia Catania
Journal:  Toxicol Appl Pharmacol       Date:  2016-05-12       Impact factor: 4.219

6.  Regulation of biotransformation systems and ABC transporters by benznidazole in HepG2 cells: involvement of pregnane X-receptor.

Authors:  Juan P Rigalli; Virginia G Perdomo; Marcelo G Luquita; Silvina S M Villanueva; Agostina Arias; Dirk Theile; Johanna Weiss; Aldo D Mottino; María L Ruiz; Viviana A Catania
Journal:  PLoS Negl Trop Dis       Date:  2012-12-13

7.  Up-regulation of ATP-binding cassette transporters in the THP-1 human macrophage cell line by the antichagasic benznidazole.

Authors:  Virginia G Perdomo; Juan P Rigalli; Marcelo G Luquita; José M Pellegrino; María Laura Ruiz; Viviana A Catania
Journal:  Mem Inst Oswaldo Cruz       Date:  2016-10-24       Impact factor: 2.743

Review 8.  ROS and Trypanosoma cruzi: Fuel to infection, poison to the heart.

Authors:  Claudia N Paiva; Emiliano Medei; Marcelo T Bozza
Journal:  PLoS Pathog       Date:  2018-04-19       Impact factor: 6.823

9.  Enteric Neuronal Damage, Intramuscular Denervation and Smooth Muscle Phenotype Changes as Mechanisms of Chagasic Megacolon: Evidence from a Long-Term Murine Model of Trypanosoma cruzi Infection.

Authors:  Camila França Campos; Silvia Dantas Cangussú; Ana Luiza Cassin Duz; Christiane Teixeira Cartelle; Maria de Lourdes Noviello; Vanja Maria Veloso; Maria Terezinha Bahia; Camila Megale Almeida-Leite; Rosa Maria Esteves Arantes
Journal:  PLoS One       Date:  2016-04-05       Impact factor: 3.240

10.  Prostaglandin F2α synthase in Trypanosoma cruzi plays critical roles in oxidative stress and susceptibility to benznidazole.

Authors:  Paola García-Huertas; Ana María Mejía-Jaramillo; Carlos Renato Machado; Anna Cláudia Guimarães; Omar Triana-Chávez
Journal:  R Soc Open Sci       Date:  2017-09-20       Impact factor: 2.963

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.